- Stocks
- Healthcare
- NASDAQ: EXAS

Price (delayed)

$120.96

Market cap

$18.2B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.13

Enterprise value

$19.1B

EXAS's gross profit has surged by 84% year-on-year and by 17% since the previous quarter

EXAS's revenue has surged by 82% year-on-year and by 17% since the previous quarter

The company's quick ratio has surged by 127% YoY but it fell by 6% QoQ

Exact Sciences's EPS has plunged by 117% from the previous quarter and by 25% YoY

The company's net income has shrunk by 116% QoQ and by 55% YoY

What are the main financial stats of EXAS

Market
Valuations
Earnings

Shares outstanding

150.42M

Market cap

$18.2B

Enterprise value

$19.1B

Price to earnings (P/E)

N/A

Price to book (P/B)

7.77

Price to sales (P/S)

13.75

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

14.46

Revenue

$1.32B

EBIT

-$440.18M

EBITDA

-$276.78M

Free cash flow

-$91.69M

Per share
Balance sheet
Liquidity

EPS

-$2.13

Free cash flow per share

-$0.61

Book value per share

$15.56

Revenue per share

$8.8

TBVPS

$14.95

Total assets

$4.35B

Total liabilities

$2.02B

Debt

$1.71B

Equity

$2.34B

Working capital

$1.35B

Debt to equity

0.73

Current ratio

6.35

Quick ratio

5.89

Net debt/EBITDA

-3.28

Margins
Efficiency
Dividend

EBITDA margin

-21%

Gross margin

75.5%

Net margin

-25.3%

Operating margin

-34%

Return on assets

-8%

Return on equity

-13.8%

Return on invested capital

-17.1%

Return on capital employed

-10.7%

Return on sales

-33.3%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Exact Sciences stock price performed over time

Intraday

2.34%

1 week

0.35%

1 month

-2.32%

1 year

49.31%

YTD

30.8%

QTD

18.65%

How have Exact Sciences's revenue and profit performed over time

Revenue

$1.32B

Gross profit

$996.93M

Operating income

-$448.83M

Net income

-$333.78M

Gross margin

75.5%

Net margin

-25.3%

The operating income has dropped by 140% year-on-year and by 60% since the previous quarter

The company's net income has shrunk by 116% QoQ and by 55% YoY

The company's net margin has shrunk by 85% QoQ but it rose by 15% YoY

EXAS's gross profit has surged by 84% year-on-year and by 17% since the previous quarter

What is Exact Sciences's growth rate over time

What is Exact Sciences stock price valuation

P/E

N/A

P/B

7.77

P/S

13.75

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

14.46

Exact Sciences's EPS has plunged by 117% from the previous quarter and by 25% YoY

The stock's price to book (P/B) is 52% more than its last 4 quarters average of 5.1 but 9% less than its 5-year quarterly average of 8.5

The company's equity fell by 7% QoQ

EXAS's revenue has surged by 82% year-on-year and by 17% since the previous quarter

EXAS's price to sales (P/S) is 25% less than its 5-year quarterly average of 18.4 but 22% more than its last 4 quarters average of 11.3

How efficient is Exact Sciences business performance

The company's return on invested capital has shrunk by 86% YoY and by 36% QoQ

EXAS's return on assets has dropped by 82% since the previous quarter but it is up by 37% year-on-year

The ROE has plunged by 82% from the previous quarter but it has soared by 53% YoY

Exact Sciences's ROS has plunged by 53% YoY and by 42% from the previous quarter

What is EXAS's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for EXAS.

How did Exact Sciences financials performed over time

The total assets is 116% more than the total liabilities

The total assets has soared by 148% YoY but it has contracted by 2.5% from the previous quarter

EXAS's current ratio has soared by 131% YoY but it is down by 6% QoQ

The company's debt is 27% lower than its equity

EXAS's debt to equity is down by 33% year-on-year but it is up by 7% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.